fbpx Skip to main content

WEDNESDAY, Dec. 30, 2020 (HealthDay News) — Electronic cigarettes as consumer products are not associated with smoking cessation in observational studies, according to a review published online Dec. 22 in the American Journal of Public Health.

Richard J. Wang, M.D., from the University of California in San Francisco, and colleagues conducted a systematic review of 64 papers (55 observational studies and nine randomized clinical trials [RCTs]) to examine the association between e-cigarette use and quitting cigarettes.

The researchers found that e-cigarette consumer product use was not associated with quitting in observational studies of all adult smokers (odds ratio, 0.947; 95 percent confidence interval, 0.772 to 1.160) and smokers motivated to quit smoking (odds ratio, 0.851; 95 percent confidence interval, 0.684 to 1.057). Daily e-cigarette use was associated with more quitting (odds ratio, 1.529; 95 percent confidence interval, 1.158 to 2.019), while less quitting was seen in association with less-than-daily use (odds ratio, 0.514; 95 percent confidence interval, 0.402 to 0.665). E-cigarette use was associated with more quitting in RCTs that compared quitting among smokers who were provided e-cigarettes to smokers provided with conventional therapy (relative risk, 1.555; 95 percent confidence interval, 1.173 to 2.061).

“It’s important to recognize that in clinical trials, when certain e-cigarette devices are treated more like medicine, there may actually be an effect on quitting smoking,” Wang said in a statement. “But that needs to be balanced against the risks of using these devices.”

Abstract/Full Text (subscription or payment may be required)

You May Also Like::  Female Doctors Less Likely to Be Promoted to Upper Faculty Ranks

“Keeping up with the indications and adverse reactions to immune checkpoint inhibitors can be a full-time job. Cutaneous side effects occur in up to 45% of patients treated with ipilimumab and 34% of patients treated with nivolumab and pembrolizumab.” https://bit.ly/3FGtxtd

.@spfnomt: This month’s #DermWorld article “Estate planning 101” is especially important for young physicians to read. The long, all-consuming years between adolescence and physicianhood can become a blur...https://bit.ly/3FxOtCv

That’s a wrap #AAD2023! 5 days of soaking up knowledge from dermatologists on topics such as hidradenitis, melasma, & dietary triggers of common dermatoses.

I LOVED the #womenshealth focused sessions on vulvar dermatoses and pregnancy medication safety.


New approach uses microbiome to treat skin disease by repairing the injured microbiome that allowed inflammation to flare up in the first place, rather than reducing the inflammation after the fact. https://bit.ly/3Jt6H9v

Load More